Locations:
SearchAdvertisement
Timing and type of side effects differ greatly from chemotherapy
Dedicated multidisciplinary teams support 84 ultra-rare cancers
New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues
Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Early communication between oncologists and ophthalmologist warranted
Long-term relationship building and engagement key to gaining community trust
FDA-approved therapy offers promise for patients with castrate-resistant prostate cancer
Breaking through barriers in cancer care
The cornerstone of a successful doctor-patient relationship
Dr. Aaron Gerds argues for more balance in safety reporting
Advertisement
Advertisement